The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
المخرجات
Research outputs
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
Background Early prophylactic low-dose hydrocortisone has been proposed to reduce inflammation and to compensate for relative adrenal insufficiency in extremely preterm infants. Its overall balance of benefit and risk remains uncertain. Objective To evaluate whether hydrocortisone initiated within the first 24–48 h after birth reduces bronchopulmonary dysplasia (BPD) and mortality in infants born before 30 weeks' gestation. Methods This systematic review and meta-analysis followed PRISMA 2020 guidance and was registered in PROSPERO. PubMed, Cochrane CENTRAL, Scopus, and Web of Science were searched from inception to May 2026. Eligible studies enrolled infants born before 30 weeks' gestation who received early prophylactic systemic hydrocortisone at a low dose. Low dose was defined as a starting dose of no more than 2.0 mg/kg/day, begun within 24–48 h of birth. The comparator was placebo or no hydrocortisone. Randomized and quasi-randomized trials, their follow-up reports, and comparative observational studies were eligible. Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs). Results Fourteen studies with 3,416 infants were included. Early hydrocortisone did not significantly improve survival without BPD at 36 weeks' postmenstrual age (RR: 1.07, 95% CI: 0.97–1.19, p = 0.18). It also did not significantly reduce BPD at 36 weeks (RR: 0.94, 95% CI: 0.85–1.04, p = 0.25) or mortality before discharge (RR: 1.07, 95% CI: 0.77–1.49, p = 0.69). The duration of respiratory support and the need for oxygen at discharge were similar between groups. Subgroup analyses suggested a possible benefit in infants exposed to chorioamnionitis and in those born before 26 weeks, but these findings were exploratory. Hydrocortisone increased the risk of late-onset sepsis (RR: 1.19, 95% CI: 1.05–1.35, p = 0.01). Gastrointestinal perforation, necrotizing enterocolitis, major neonatal morbidities, and the available neurodevelopmental outcomes did not differ significantly between groups. Conclusion Current evidence does not support the routine use of early prophylactic hydrocortisone in all extremely preterm infants. Adequately powered trials and individual patient data analyses are needed to identify the subgroups most likely to benefit and to clarify long-term safety. Systematic Review Registration https://www.crd.york.ac.uk/prospero/view/CRD420261402317 , PROSPERO CRD420261402317.
Background/Objectives: Children with Down syndrome are at increased risk of obstructive sleep apnea (OSA), which cannot be reliably excluded by symptoms or examination. Saudi evidence remains limited. This review synthesizes international and Saudi evidence and proposes a pediatric care pathway incorporating the transition to adult services. Methods: We conducted a structured narrative review of the English-language literature identified through PubMed/MEDLINE, selected journal websites, and reference lists. The review focused on publications from January 2018 to 17 September 2026, retaining relevant earlier studies. Evidence was synthesized qualitatively without a new meta-analysis or formal risk of bias assessment. Results: Published international estimates indicate that OSA affects approximately 50–79% of children with Down syndrome. American Academy of Pediatrics guidance recommends polysomnography (PSG) at ages 3–4 years regardless of symptoms, with earlier assessment when indicated. Nonrandomized infant intervention studies suggest potential benefits but do not establish an optimal universal screening schedule. Saudi evidence includes a small earlier PSG referral cohort and more recent caregiver surveys; no nationally representative PSG-confirmed prevalence study was identified. Arabic questionnaire validation in a mixed pediatric referral cohort does not establish Down syndrome-specific diagnostic accuracy. Published treatment evidence indicates that adenotonsillectomy often improves OSA, although residual disease commonly requires objective reassessment and individualized management. Conclusions: The evidence supports age-based PSG, earlier assessment when indicated, postoperative reassessment, and individualized multidisciplinary care. Building on this evidence, we propose a Saudi pathway linking referral tracking, family-centered positive airway pressure support, and coordinated transition. Regional networks and registry development remain unevaluated implementation proposals requiring stakeholder consultation, resource assessment, and pilot testing; they do not constitute an endorsed national guideline.
Down syndromeobstructive sleep apneasleep-disordered breathingpolysomnography screening
Abstract Background Melatonin is an endogenous hormone that regulates the body’s sleep-wake cycles. Due to several clinical trials, it is currently used as an exogenous supplement in pediatric patients who suffer from sleep-onset insomnia (SOI). Consequently, this systematic review and meta-analysis aimed to assess the evidence for the clinical efficacy of melatonin for SOI in children aged 6–12. Methods This systematic review and meta-analysis evaluated the efficacy and safety of Melatonin for sleep-onset insomnia in children aged 6–12 by conducting literature searches in PubMed (97), Google Scholar (111), OVID (33), and Web of Science (156) databases. We performed statistical tests using RevMan for meta-analysis. Heterogeneity was evaluated using the I2 statistic. To maintain the validity of the studies, each included study was assessed by the Cochrane Collaboration Risk of Bias (ROB) tool. The outcomes investigated were sleep onset time (SOT), sleep onset latency (SOL), total sleep time (TST), all-cause dropout rates, and adverse-event dropout rates. Results Three hundred ninety-eight records were identified, and 10 randomized clinical trials met the inclusion criteria. The results demonstrated that melatonin treatment group was associated with an earlier sleep onset time compared with placebo with a mean difference (MD) of -0.48 h (approximately 29 min earlier) (95% confidence interval [CI]: -0.93 to -0.02 h, p = 0.04). The heterogeneity between studies was moderate (I2 = 63%). On the other hand, it was noted that there has been noticed there was a remarkable reduction in sleep onset latency with melatonin compared to placebo, with an MD of -0.38 (95% CI: -0.57 to -0.20, p < 0.0001), with high heterogeneity (I2 = 82%). Conclusion Our study confirmed that melatonin has a marked effect regarding Sleep-onset insomnia in childhood. Therefore, we found there was a statistical and clinical improvement in sleep parameters such as sleep onset time (SOT) and total sleep time (TST) which demonstrated the safety and efficacy of melatonin. However, long-term efficacy and safety need to be addressed, especially in the pediatric population.
American Journal of Pediatrics · vol. 12 (3) · 87-102
Background: Parapneumonic effusion (PPE) and empyema remain serious complications of childhood pneumonia associated with significant morbidity despite advances in antimicrobial therapy and surgical techniques. Accurate disease staging and timely stage-directed intervention are fundamental to optimal outcomes. Objective: To provide a current, evidence-based synthesis of the definition, etiology, diagnosis, and management of complicated pneumonia in children, with particular focus on areas of ongoing clinical controversy. Methods: A narrative review incorporating randomized controlled trials, systematic reviews, meta-analyses, Cochrane reviews, and international clinical guidelines published between 2016 and 2026 was conducted. PubMed was searched through May 2026 using terms including pneumonia, complicated pneumonia, parapneumonic effusion, empyema, VATS, fibrinolysis, decortication, and pediatric. Results: Chest radiography remains the initial imaging modality for suspected complicated pneumonia, with lateral decubitus views needed to assess pleural fluid mobility. However, chest ultrasonography is the preferred imaging modality for evaluating parapneumonic effusions and empyema because of its superior diagnostic accuracy, ability to characterize pleural collections, and absence of ionizing radiation. Management is stage-dependent, combining targeted antibiotic therapy with procedural intervention when indicated. Image-guided pigtail catheter drainage with intrapleural fibrinolytic therapy is effective for most patients. VATS demonstrates particular utility during the fibrinopurulent stage. No single fibrinolytic agent has demonstrated clear superiority; however, tissue plasminogen activator is most widely employed. Open decortication remains reserved for refractory or advanced-stage disease. Conclusion: Early diagnosis, appropriate antibiotics, and prompt intervention or surgery are all important for optimal care. The optimal outcomes require a multidisciplinary, individualized, stage-directed approach. Interventional radiology is appropriate for single loculations, while early VATS is favored for thick pleural rind or multiple loculations. Further high-quality prospective research is needed to establish definitive treatment algorithms.
Abstract Background Pediatric respiratory infections are a leading cause of morbidity and mortality globally, representing a major health challenge in children. Research Gap Despite extensive studies on epidemiology, clinical management, and specific pathogens, no bibliometric analysis has systematically evaluated the most influential research in this field. Objectives This study aimed to evaluate the characteristics of the top 50 most-cited articles on pediatric respiratory infections and to identify emerging research trends. Methods The Web of Science database was searched without publication year restrictions. Independent reviewers screened studies based on predefined inclusion and exclusion criteria. Data were extracted using a standardized form, including study details. Results The 50 most-cited articles ranged from 34 to 384 citations and showed a right-skewed distribution with a sharp drop after the top ten. Publication years ranged from 1978 to 2021, with over half published in the 2010s. Articles appeared in 31 journals, with Pediatrics contributing five. Leading countries were the United States (18%), China (12%), and Canada (10%), with research largely concentrated in high-income regions and limited multicenter collaboration. Cohort studies dominated (66%), while randomized trials (12%) and reviews/meta-analyses (16%) were less common. Research clustered around three themes: clinical outcomes (e.g., pneumonia, bronchiolitis); viral etiology/diagnostics (e.g., RSV, SARS-CoV-2); and antimicrobial stewardship. Conclusion Over the past decades, pediatric respiratory infection research has developed but remains unbalanced, relying heavily on observational evidence from high-income countries, with limited randomized trials, systematic reviews, multicenter collaborations, and LMIC-led studies. These findings provide insights that may direct researchers to identify potential focal points and guide future research in the field.
Frontiers in Pediatrics · vol. 14 · 1780809-1780809
Introduction Ureaplasma colonization in preterm infants is linked to pulmonary inflammation and bronchopulmonary dysplasia (BPD). Evidence regarding the effectiveness of macrolides, including their prophylactic role in preventing BPD, remains limited. This review aimed to assess whether azithromycin reduces the incidence of BPD or death in preterm infants, with or without Ureaplasma colonization, compared with placebo or no intervention. Methods We followed PRISMA guidelines and searched PubMed, Cochrane Library, Embase, and Google Scholar for randomized controlled trials (RCTs) evaluating azithromycin in preterm infants with unknown or confirmed Ureaplasma infection. Primary outcomes were death and BPD, while secondary outcomes included hospital stay, adverse events, and ventilation or oxygen duration. Studies not focused on preterm infants, lacking Ureaplasma status, or not randomized were excluded. Results A meta-analysis of six randomized controlled trials, including 1,446 preterm infants with unknown or confirmed Ureaplasma status and sample sizes ranging from 80 to 796, compared azithromycin with placebo. No significant reduction was observed in BPD incidence [risk ratio (RR) = 0.92, 95% CI: 0.78–1.09, p = 0.35] or mortality (RR = 0.88, 95% CI: 0.66–1.18, p = 0.39). Heterogeneity was low for mortality ( I 2 = 0%) and moderate for BPD ( I 2 = 61%). Secondary outcomes showed no significant differences in mechanical ventilation days (mean difference=0.07, 95% CI: −0.78 to 0.33, p = 0.58), supplemental oxygen requirement (mean difference=−0.45, 95% CI: −0.98 to 0.07, p = 0.09), or hospitalization duration (mean difference=−0.02, 95% CI: −0.19 to 0.15, p = 0.85). Heterogeneity ( I 2 ) was 94% for supplemental oxygen, 71% for mechanical ventilation, and 0% for hospitalization duration. Risk-of-bias assessment identified two studies with low risk and four with unclear risk, indicating acceptable methodological quality. Conclusion This systematic review and meta-analysis evaluated azithromycin efficacy and safety in preventing BPD and reducing mortality in preterm infants. No significant reduction in BPD or mortality was observed with azithromycin compared with placebo. Secondary outcomes, including ventilation duration, supplemental oxygen use, and hospitalization length, showed no improvement. However, heterogeneity among secondary outcomes was moderate to high, and included studies were limited. Systematic Review Registration PROSPERO CRD42024572847.
Electronic medical records (EMRs) are critical, highly sensitive private information in health sector, and manage patient health information. The purpose of the study identifies a unique opportunity to develop a secure for maternal child health care. This work uses the Scopus, PubMed, and Web of Science databases to analyse the most productive authors, journals, institutions, and countries, as well as the most cited papers and the citing articles. The investigation used bibliometric analysis to identify the bibliographic data from 501 articles published from 2011 and 2025 and implementation of EMRs for maternal and child healthcare. Based on the findings, the issue is multifaceted and involves various stakeholders, including health care providers, patients, and technological issues within the health sectors. The proposed work can significantly reduce the turnaround time for EMRs sharing, improve decision making for medical care, and reduce the overall cost of medical instruments.
electronic health recordsmaternal carechild health carehealth information security
BACKGROUND: Dupilumab is a human monoclonal antibody targeting the IL-4 receptor. There is a paucity of evidence regarding its efficacy and safety in pediatrics. Pediatric-specific data are limited, and most evidence comes from recent phase 3 trials and post hoc analyses. OBJECTIVE: To summarize the current evidence of the efficacy, safety, and biomarker effects of dupilumab in children with moderate-to-severe asthma, while identifying key gaps in the pediatric evidence base. METHODS: This study is a systematic review following PRISMA guidelines, and aims to assess the efficacy, safety, and biomarker response of dupilumab in pediatric patients with moderate to severe asthma. We evaluated the studies using the Cochrane Risk of Bias Tool 2.0. RESULTS: Six studies from 2021 to 2024 met the inclusion criteria: three of them are phase 3 randomized controlled trials and the other three post hoc analyses, mostly including children aged 6-11 years with type 2 inflammation, defined by elevated blood eosinophils and/or FeNO. Both allergic and nonallergic asthma phenotypes were represented across studies, with post hoc analyses indicating consistent benefit in each group. Dupilumab decreased the rate of severe exacerbations annually by 59.3% in children with type 2 inflammation. The study populations are mainly children between 6 and 11 years of age with moderate-to-severe asthma, characterized by eosinophilic or allergic phenotypes (type 2 asthma), including those with elevated blood eosinophils and/or FeNO levels. Dupilumab reduced the annual rate of severe exacerbation by ~59%, with greater reductions in children with FeNO ≥50 ppb (69%) or eosinophils ≥300 cells/µL (65%). The lung function showed improvement by 0.15-0.30 L in pre-bronchodilator FEV₁, accompanied by gains in asthma control and quality of life. Biomarker reductions (FeNO, eosinophils, IgE, TARC) were consistent across phenotypes. Adverse event rates were like placebo; eosinophilia and injection site reactions were more common but usually mild. CONCLUSION: This systematic review provides an early synthesis of emerging pediatric phase 3 evidence on dupilumab. While results suggest substantial benefits in reducing exacerbations, improving lung function, and modulating type 2 biomarkers, the evidence remains limited to short-term studies in a narrow age range. Longer-term follow-up, broader age representation, and real-world data are needed to define the long-term role of dupilumab in pediatric asthma. Prospero Code: CRD42024557750.
Frontiers in Pediatrics · vol. 12 · 1455950-1455950
Introduction Pressure ulcers are a significant concern in pediatric intensive care units, with prevalence rates ranging from 0.8% to 27%. They pose serious physical and psychological challenges, particularly in neonatal and pediatric intensive care units (NICU and PICU). This study explores nursing strategies, attitudes, and barriers toward pressure ulcer prevention in NICU and PICU settings. Methods Using a descriptive study design, data were collected from 80 nurses working in NICU and PICU through validated questionnaires, including a demographic profile and a pressure ulcer survey. Descriptive statistics were employed to calculate mean scores and percentages, while inferential statistics assessed associations between variables. Results The study revealed specific nursing strategies, along with significant barriers and attitudes toward pressure ulcer prevention in NICU and PICU. The total attitude mean score was 3.57, with the highest positive response (mean = 4.29) for “most pressure sores can be avoided”, and the highest negative response (mean = 3.86) for “pressure sore prevention is a low priority for me”. Among participants, 72.5% conducted risk assessments on all patients, 60% had written prevention care plans, and 76.3% implemented preventive strategies. Barriers such as staff shortages and time constraints were reported by 76.2% of nurses. Multivariate analysis indicated that nurses with more than 10 years of qualification (OR = 3.67) and permanent staff with over 10 years of employment (OR = 4.31) were significantly more likely to engage in preventive practices. The use of a pressure ulcer grading tool (OR = 2.49, P < 0.05) and participation in formal training (OR = 3.14, P < 0.05) were also positively associated with preventive practices. Discussion These findings underscore the importance of structured assessment tools, ongoing education, and the need to foster positive attitudes among nurses to effectively reduce pressure ulcer prevalence and enhance patient outcomes in NICU and PICU settings.
pressure ulcer preventionnurses' attitudesnursing behaviorbarriers to prevention
INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts both pediatrics and adults. Despite the availability and proven efficacy of systemic medications, there remains a critical issue of non-adherence among patients. This study aimed to assess adherence to systemic therapy among Saudi adult patients with AD. METHODS: The study employed a cross-sectional study with an online questionnaire that was distributed among a convenience sample of 1,154 adult patients with AD in Saudi Arabia. In addition to descriptive statistical analysis, Pearson's correlation and chi-squared tests were used to determine the correlations between adherence to systemic therapy for AD and its predictable factors. RESULTS: AD was diagnosed over five years in 61.3% of the participants. The vast majority of those diagnosed with AD (73%) were prescribed systemic medications, with a moderate level of adherence to this therapy. While adherence to systemic therapy significantly correlated with improved quality of life, factors including forgetfulness, side effect concerns, patient's belief in medication importance, disease severity, and medication complexity impacted adherence to this mode of therapy. Factors including patient's belief in medication importance, disease severity, and medication complexity impacted adherence. CONCLUSION: The findings of this study highlight the need for multifaceted interventions to improve adherence to systemic therapy for AD. Addressing patient concerns about the use of systemic therapy for AD and reinforcing the importance of medication use for long-term disease management and quality-of-life improvement is recommended to explore the barriers to adherence and enhance compliance to systemic therapy in this population.
Cranial epidermoid cysts are relatively rare. More frequently reported in middle-aged men with a wide variety of signs and symptoms such as headache, seizures, cerebellar and cranial nerve deficits/visual disturbance. The approach for surgical removal of the cyst depends on its size and location. In addition, a multidisciplinary team must be involved due to the common occurrence of misdiagnosis. We present the unusual age of presentation for intradiploic epidermoid cysts. A 14-year-old boy is complaining of a 2-month history of painless progressive swelling of the right eyebrow. Magnetic resonance imaging revealed an intradiploic cystic mass within the right frontal bone. The cystic mass was removed, and histological examination confirmed the diagnosis of an epidermoid cyst. This case illustrated the potential of developing intradiploic epidermoid cysts in pediatrics.
International Journal of Life Science and Pharma Research · L37-L49
Neurogenic bowel dysfunction (NBD) is fecal incontinence or constipation which is prevalent in kids with both congenital and acquired neurological disorders. NBD results from loss of normal sensory or motor control and may include both the upper and the lower gastrointestinal (GI) tract Constipation and fecal incontinence are frequent symptoms of neurogenic bowel dysfunction (NBD), which makes it a challenging condition to treat. Also, they have a major impact on quality of life and dignity. Bowel dysfunction is less studied compared to neurogenic bladder, generally prevelant in spina bifida, but practically as prevalent in other neurological conditions. Generally, the objective of neurogenic bowel management is to achieve complete emptying of the rectum on a systematic basis. This may be accomplished through with a multidimensional approach containing of conservative, medical and even surgical approaches. A modified Delphi procedure was used to construct a statement document. This paper discusses the various causes of paediatric NBD. Our aim is to enhance clinical management, numerous therapeutic techniques are given. Due to both the improved survival rate and better diagnosis, there are more children and teenagers with NBD. The number of children and adolescents with NBD is growing as a result of better diagnosis and a greater survival rat NBD can cause either faecal incontinence or constipation, or both, with a fair amount of predictability. However, each patient will experience NBD in a different way depending on a variety of underlying conditions and coexisting conditions. Due to the status of the affected child and caregivers, management of NBD should be individualized using a combined multidisciplinary therapy.
International Journal of Life Science and Pharma Research
Neurogenic bowel dysfunction (NBD) is fecal incontinence or constipation which is prevalent in kids with both congenital and acquired neurological disorders. NBD results from loss of normal sensory or motor control and may include both the upper and the lower gastrointestinal (GI) tract Constipation and fecal incontinence are frequent symptoms of neurogenic bowel dysfunction (NBD), which makes it a challenging condition to treat. Also, they have a major impact on quality of life and dignity. Bowel dysfunction is less studied compared to neurogenic bladder, generally prevelant in spina bifida, but practically as prevalent in other neurological conditions. Generally, the objective of neurogenic bowel management is to achieve complete emptying of the rectum on a systematic basis. This may be accomplished through with a multidimensional approach containing of conservative, medical and even surgical approaches. A modified Delphi procedure was used to construct a statement document. This paper discusses the various causes of paediatric NBD. Our aim is to enhance clinical management, numerous therapeutic techniques are given. Due to both the improved survival rate and better diagnosis, there are more children and teenagers with NBD. The number of children and adolescents with NBD is growing as a result of better diagnosis and a greater survival rat NBD can cause either faecal incontinence or constipation, or both, with a fair amount of predictability. However, each patient will experience NBD in a different way depending on a variety of underlying conditions and coexisting conditions. Due to the status of the affected child and caregivers, management of NBD should be individualized using a combined multidisciplinary therapy.
Coronavirus disease 2019 (COVID-19) is a recent epidemic disease caused by severe acute respiratory syndrome virus type 2 (SARS-CoV-2). In pregnancy, SARS-Cov-2 infection creates additional alarm due to concerns regarding the potential for transmission from the mother to the baby during both the antenatal and postpartum times. In general, breastfeeding is seldom disallowed because of infection of the mother. However, there are few exceptions with regards to certain infectious organisms with established transmission evidence from mother to infant and the link of infection of a newborn with significant morbidity and mortality. It is confirmed that pregnant women can become infected with SARS-CoV-2, although the debate on the possible vertical transmission of SARS-CoV-2 infection during pregnancy is still open. In this regard, the literature is still poor. On the contrary, the information on the safety of breastfeeding even during infections seems reassuring when the mother takes the necessary precautions. However, there are still answered questions regarding the precautions to be taken during breastfeeding by COVID-19 patients. This paper reviews the existing answers to these and many other questions. This review therefore presents a summary of the present-day understanding of infection with SARS-CoV-2 and discusses the answers around the maternal transmission of COVID-19 and the potential threat of breastfeeding to babies born to infected pregnant mothers. In conclusion, intrauterine transmission of SARS-CoV-2 infection is less likely to occur during pregnancy. Most studies suggest that COVID-19 is not transmitted through breast milk. Correspondingly, COVID-19-infected neonates might acquire the infection via the respiratory route because of the postnatal contact with the mother rather than during the prenatal period. International organizations encourage breastfeeding regardless of the COVID-19 status of the mother or child as long as proper hygienic and safety measures are adhered to so as to minimize the chance of infant infection by droplets and direct contact with the infected mother. Pasteurized donor human milk or infant formula as supplemental feeding can be quite beneficial in the case of mother–infant separation till breastfeeding is safe.
International Journal of Pediatrics and Adolescent Medicine · vol. 9 (1) · 62-65
In this study, dosing instructions in package inserts of all 12 paediatric liquid acetaminophen products registered in pharmacies in the Kingdom of Saudi Arabia were analysed to determine the potential for administering a supratherapeutic dose of acetaminophen. Doses in millilitres were calculated as mg/kg for four age groups: three months old, one year old, six years old, and twelve years old, and based on the 3rd, 50th, and 75th weight percentiles of each age group. Acetaminophen concentrations in the products varied, and only two products included Arabic language instructions. The dosing instructions in eight products included an age overlap. The most affected age group was the 1-year-old group, with 21 supratherapeutic doses across all 12 products. The least affected age group was the 12-year-old group, with 8 supratherapeutic doses in total. The absence of strict supervision and monitoring of labels of paediatric liquid acetaminophen products increases the risk of liver toxicity in children. Therefore, we call for an immediate standardisation of all dosing instructions regarding the dose per weight and the inclusion of instructions in Arabic.